Somatostatin (SST), a small cyclic neurpeptide, has been applied for treating pancreatic adenocarcinoma in pre-clinical trials as adjuvants on account of their inhibitory effects on cell proliferation and growth hormone release [29, 30]. Here, GH1 is linked to pancreatic adenocarcinoma.